Pituitary tumour transforming gene in endocrine cancer

Clinical Endocrinology

Volumn 58, Issue 6, 2003, Pages 673-682

  McCabe, Chris J ^b   Heaney, Anthony P ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; ESTROGEN;

GENE CONTROL; GENE OVEREXPRESSION; HORMONAL REGULATION; HUMAN; HYPOPHYSIS TUMOR; MALIGNANT TRANSFORMATION; NONHUMAN; ONCOGENE; PITUITARY TUMOR TRANSFORMING GENE; PRIORITY JOURNAL; REVIEW; THYROID CANCER;

ANIMALS; ENDOTHELIAL GROWTH FACTORS; ESTROGENS; FEMALE; FIBROBLAST GROWTH FACTOR 2; GENE EXPRESSION REGULATION; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOKINES; MALE; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; PITUITARY NEOPLASMS; RATS; RNA, MESSENGER; THYROID NEOPLASMS; THYROTROPIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0038807897     PISSN: 03000664     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2265.2003.01687.x     Document Type: Review

References (115)

1. Asa, S.L., Penz, G., Kovacs, K. & Exrin, C. (1982) Prolactin cells in the human pituitary. Archives of Pathology and Laboratory Medicine, 106, 360-363.
2. Atkin, S.L., Green, V.L., Hipkin, L.J., Landolt, A.M., Foy, P.M., Jeffreys, R.V. & White, M.C. (1997) A comparison of proliferation indices in human anterior pituitary adenomas using formalin-fixed tissue and in vitro cell culture. Journal of Neurosurgery, 87, 85-88.
3. Baird, A., Mormede, P, Ying, S.P., Wehrenberg, W.B., Ueno, N., Ling, N. & Guillem, R. (1985) A nonmitogenic pituitary function of fibroblast growth factor: regulation of thyrotrophin and prolactin secretion. Proceedings of the National Academy of Science of the USA, 82, 5545-5549.
4. Bikfalvi, A., Klein, S., Pintucci, G., Rifkin, D.B. & Biological roles of fibroblast growth factor-2. (1997) Endocrine Reviews, 18, 26-45.
5. Black, E.G., Logan, A., Davis, J.R. & Sheppard, M.C. (1990) Basic fibroblast growth factor affects DNA synthesis and cell function and activates multiple signalling pathways in rat thyroid FRTL5 and pituitary GH3 cells. Journal of Endocrinology, 127, 39-46.
6. Bohm, J.P., Niskanen, L.K., Pirinen, R.T., Kiraly, K., Kellokoski, J.K., Moisio, K.I., Eskelinen, M.J., Tulla, H.E., Hollmen, S., Alhava, E.M. & Kosma, V.M. (2000) Reduced CD44 standard expression is associated with tumour recurrence and unfavourable outcome in differentiated thyroid carcinoma. Journal of Pathology, 192, 321-327.
7. Bounacer, A., Wicker, R., Caillou, B., Cailleux, A.F., Sarasin, A., Schlumberger, M. & Suarez, H.G. (1997) High prevalence of activating RET proto-oncogene rearrangements in thyroid tumors from patients who have received external radiation. Oncogene, 15, 1263-1273.
8. Buchfelder, M., Fahlbusch, R., Adams, E.F., Kiesewetter, F. & Thierauf, P. (1996) Proliferation parameters for pituitary adenomas (review). Acta Neurochirurgica Supplementum, 65, 18-21.
9. Cai, W.Y., Alexander, J.M., Hedley-Whyte, E.T., Scheithauer, B.W., Jameson, J.L., Zervas, N.T. & Klibanski, A. (1994) Ras mutations in human prolactinomas and carcinomas. Journal of Clinical Endocrinology and Metabolism, 78, 89-93.
10. Carrasco, N. (1993) Iodide transport in the thyroid gland. Biochemica Biophysica Acta, 1154, 65-82.
11. Chaelis, C., Ciosk, R. & Nasmyth, K. (1997) Cohesins: chromosomal proteins that prevent premature separation of sister chromatids. Cell, 91, 35-45.
12. Clark, O.H., Gerend, P.R., Davis, B.A., Goretzki, P.E. & Hoffman, P.G. (1985) Estrogen and thyroid-stimulating hormone (TSH) receptors in neoplastic and nonneoplastic human thyroid tissues. Journal of Surgery Research, 38, 89-96.
13. Cohen-Fix, O., Peters, J.M., Kirschner, M.W. & Koshland, D. (1996) Anaphase initiation in Saccharomyces cerevisiae is controlled by the APC-dependent degradation of the anaphase inhibitor Pdslp. Genes and Development, 10, 3081-3093.
14. Cooper, G.M. (1995) Oncogenes, 2nd edn. Jones and Bartlett, Boston.
15. Costello, R.T. (1936) Subclinical adenoma of the pituitary gland. American Journal of Pathology, 12, 205-215.
16. Dominguez, A., Ramos-Morales, F., Romero, F., Rios, R.M., Dreyfuss, F., Tortolero & Pintor-Toro, J.A. (1998) hpttg, a human homologue of rat pttg, is overexpressed in hematopoietic neoplasms. Evidence for a transcriptional activation function of hPTTG. Oncogene, 17, 2187-2193.
17. Dulgeroff, A.J. & Hershman, J.M. (1994) Medical therapy for differentiated thyroid carcinoma. Endocrine Reviews, 15, 500-515.
18. Eggo, M.C., Hopkins, J.M., Franklyn, J.A., Johnson, G.D., Sanders, D.S. & Sheppard, M.C. (1995) Expression of fibroblast growth factors in thyroid cancer. Journal of Clinical Endocrinology and Metabolism, 80, 1006-1011.
19. Ezzat, S., Zheng, L., Zhu, X.F., Wu, G.E. & Asa, S.L. (2002) Targeted expression of a human pituitary tumor-derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis. Journal of Clinical Investigation, 109, 69-78.
20. Fagin, J.A. (2000) Molecular genetics of thyroid follicular cells. In: Braverman, L.E. & Utiger, R.D., eds. The Thyroid. Lippincott, Williams & Wilkins, Philadelphia, USA.
21. Fang, G., Yu, H. & Kirschner, M.W. (1998) The checkpoint protein MAD2 and the mitotic regulator CDC20 form a ternary complex with the anaphase-promoting complex to control anaphase initiation. Genes and Development, 12, 1871-1883.
22. Farid, N.R., Shi, Y. & Zou, M. (1994) Molecular basis of thyroid cancer. Endocrine Reviews, 15, 202-232.
23. Ferrara, N. & Davis-Smyth, T. (1997) The biology of vascular endothelial growth factor. Endocrine Reviews, 18, 4-25.
24. Folkman, J. (1992) The role of angiogenesis in tumour growth. Seminars in Cancer Biology, 3, 65-71.
25. Fuggazola, L., Pilotti, S. & Pinchera, A. (1995) Oncogenic rearrangements of the RET proto-oncogene in papillary thyroid carcinoma from children exposed to the Chernobyl reactor accident. Cancer Research, 55, 5617-5620.
26. Funabiki, H., Yamano, H., Kumada, K., Nagao, K., Hunt, T. & Yanagida, M. (1996) Cut2 proteolysis required for sister-chromatid seperation in fission yeast. Nature, 381, 438-441.
27. Gittoes, N.J.L., McCabe, C.J., Verhaeg, J., Sheppard, M.C. & Franklyn, J.A. (1997) Thyroid hormone and estrogen receptor expression in normal pituitary and 'non-functioning' tumors of the anterior pituitary. Journal of Clinical Endocrinology and Metabolism, 82, 1960-1967.
28. Godspodarowicz, D., Ferrara, N., Weigerer, L. & Neufeld, G. (1987) Structural characterization and biological functions of fibroblast growth factor. Endocrine Reviews, 8, 95-114.
29. Grebe, S.K.G., Hay, I.D., Jenkins, R.B., Wu, S.-C., Maciel, L. & Eberhardt, N.L. (1996) Frequent loss of heterozygosity on the distal portions of chromosome 3p and 17p in follicular thyroid carcinoma is rarely associated with mutations in the known tumor suppressor genes VHL and p53 (abstract). Thyroid, 137, S70-S79.
30. Heaney, A.P., Horwitz, G.A., Wang, Z., Singson, R.S. & Melmed, S. (1999) Early involvement of oestrogen-induced pituitary tumor transforming gene (PTTG1) and fibroblast growth factor (bFGF) expression in prolactinoma pathogenesis. Nature Medicine, 5, 1317-1321.
31. Heaney, A.P., Singson, R., McCabe, C.J., Nelson, V., Nakashima, M. & Melmed, S. (2000) Pituitary tumor transforming gene: a novel marker in colorectal tumors. Lancet, 355, 716-719.
32. Heaney, A.P., Nelson, V., Fernando, M. & Horwitz, G. (2001) Transforming events in thyroid tumorigenesis and their association with follicular lesions. Journal of Clinical Endocrinology and Metabolism, 86, 5025-5032.
33. Heaney, A.P., Fernando, M. & Melmed, S. (2002) Functional role of estrogen in pituitary tumor pathogenesis. Journal of Clinical Investigations, 109, 277-283.
34. Hill, D.J., Phillips, I.D., Wang, J.F. & Becks, G.P. (1994) Basic fibroblast growth factor (basic FGF) in isolated ovine thyroid follicles: thyrotropin stimulation and effects of basic FGF on DNA synthesis, iodine uptake and organification, and the release of insulin-like growth factors (IGFs) and IGF-binding proteins. Thyroid, 4, 77-85.
35. Hosoe, S. (1996) Search for the tumor-suppressor gene(s) on chromosome 5q, which may play an important role for the progression of lung cancer. Japanese Journal of Clinical Medicine, 54, 482-486.
36. Hwang, L.H., Lau, L.F., Smith, D.L., Mistrot, C.A., Hardwick, K.G., Hwang, E.S., Amon, A. & Murray, A.W. (1998) Budding yeast Cdc20: a target of the spindle checkpoint. Science, 279, 1041-1044.
37. Ishikawa, H., Heaney, A.P., Yu, R., Horwitz, G.A. & Melmed, S. (2001) Human pituitary tumor transforming gene (PTTG) induces angiogenesis and correlates with tumor vascularity. Journal of Clinical Endocrinology and Metabolism, 86, 867-874.
38. Jallepalli, P.V., Waizenegger, I.C., Bunz, F., Langer, S., Speicher, M.R., Peters, J.M., Kinzler, K.W., Vogelstein, B. & Lengauer, C. (2001) Securin is required for chromosomal stability in human cells. Cell, 105, 445-457.
39. Japon, M.A., Urbano, A.G., Saez, C., Segura, D.I., Cerro, A.L., Dieguez, C. & Alvarez, C.V. (2002) Glial-derived neurotropic factor and RET gene expression in normal human anterior pituitary cell types and in pituitary tumors. Journal of Clinical Endocrinology and Metabolism, 87, 1879-1884.
40. Joensuu, H., Klemi, P. & Eerola, E. (1986) DNA aneuploidy in follicular adenomas of the thyroid gland. American Journal of Pathology, 124, 373-376.
41. Joensuu, H. & Klemi, P.J. (1988) DNA aneuploidy in adenomas of endocrine organs. American Journal of Pathology, 132, 145-151.
42. Kakar, S.S. (1999) Molecular cloning, genomic organization, and identification of the promoter for the human pituitary tumor transforming gene (PTTG). Gene, 240, 317-324.
43. Kallio, M., Weinstein, J., Daum, J.R., Burke, D.J. & Gorbsky, G.J. (1998) Mammalian p55CDC mediates association of the spindle checkpoint protein Mad2 with the cyclosome/anaphase-promoting complex, and is involved in regulating anaphase onset and late mitotic events. Journal of Cell Biology, 141, 1393-1406.
44. Kane, L.A., Leinung, M.C., Scheithauer, B.W., Bergstralh, E.J., Laws, E.R., Groover, R.V., Kovacs, K., Horvath, E. & Zimmerman, D. (1994) Pituitary adenomas in childhood and adolescence. Journal of Clinical Endocrinology and Metabolism, 79, 1135-1140.
45. Knosp, E., Kitz, K. & Perneczky, A. (1989) Proliferation activity in pituitary adenomas: measurement by monoclonal antibody Ki-67. Neurosurgery, 25, 927-930.
46. Kovacs, K. & Horvath, E. (1986) Tumours of the pituitary gland. In: Hartmann, W.H. & Sobin, L.H., eds. Atlas of Tumour Pathology, Second Series, Fasicle 21. Armed Forces Institute of Pathology, Washington, DC.
47. Kovacs, K., Stefeaneau, L., Ezzat, S. & Smyth, H.S. (1994) Prolactin-producing pituitary adenoma in a male-to-female transsexual patient with protracted oestrogen administration. A morphologic study. Archives of Patholology and Laboratory Medicine, 118, 562-565.
48. Kramer, E.R., Scheuringer, N., Podtelejnikov, A.V., Mann, M. & Peters, J.M. (2000) Mitotic regulation of the APC activator proteins CDC20 and CDH1. Molecular Biology of the Cell, 11, 1555-1569.
49. Kroll, T.G., Saraff, P., Pecciarini, L., Chen, C.J., Mueller, E., Spiegelman, B.M. & Fletcher, J.A. (2000) PAX8-PPARgammal fusion oncogene in human thyroid carcinoma. Science, 289, 1357-1360.
50. Kubo, K., Yoshimoto, K., Yokogoshi, Y., Tsuyuguchi, M. & Saito, S. (1991) Loss of heterozygosity on chromosome 1p in thyroid adenoma and medullary carcinoma, but not in papillary carcinoma. Japanese Journal of Cancer Research, 82, 1097-1103.
51. Kupperman, E., Wofford, D., Wen, W. & Meinkoth, J.L. (1996) Ras inhibits thyroglobulin expression but not cyclic adenosine monophosphate-mediated signaling in wistar rat thyrocytes. Endocrinology, 137, 96-104.
52. Larson, G.H., Koos, R.D., Sortino, M.A. & Wise, P.M. (1990) Acute effects of basic fibroblast growth factor on secretion of prolactin as assessed by the reverse hemolytic plaque assay. Endocrinology, 126, 927-932.
53. - symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes. Journal of Clinical Endocrinology and Metabolism, 84, 3228-3234.
54. Leismann, O., Herzig, A., Heidmann, S., Lehner & C.F. (2000) Degradation of drosophila PIM regulates sister chromatid separation during mitosis. Genes and Development, 14, 2192-2205.
55. Lemoline, N.R., Mayall, E.S., Wyllie, F.S., Williams, E.D., Goyns, M., Stringer, B. & Wynford-Thomas, D. (1989) High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis. Oncogene, 4, 159-164.
56. Logan, A., Black, E.G., Gonzalez, A.M., Buscaglia, M. & Sheppard, M.C. (1992) Basic fibroblast growth factor: an autocrine mitogen of rat thyroid follicular cells. Endocrinology, 130, 2363-2372.
57. Malthiery, Y. & Lissitzky, S. (1987) Primary structure of human thyroglobulin deduced from the sequence of its 8448-base complementary DNA. European Journal of Biochemistry, 165, 491-498.
58. Marquess, E., Braverman, L.E., Lawerence, J.E., Carroll, J.S. & Seely, E.W. (2000) The effect of droloxifene and estrogen on thyroid function in postmenopausal women. Journal of Clinical Endocrinology and Metabolism, 85, 4407-4410.
59. Marsh, D.J., Zheng, Z., Zedenius, J., Kremer, H., Padberg, G.W., Larsson, C., Longy, M. & Eng, C. (1997) Differential loss of heterozygosity in the region of the Cowden locus within 10q22-23 in follicular thyroid adenomas and carcinomas. Cancer Research, 57, 50-503.
60. Matsuo, K., Tang, S.H. & Fagin, J.A. (1991) Allelotype of human thyroid tumors: loss of chromosome 11q13 sequences in follicular neoplasms. Molecular Endocrinology, 5, 1873-1879.
61. Mazzaferri, E.L. & Jhiang, S.M. (1994) Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. American Journal of Medicine, 97, 418-428.
62. McCabe, C.J., Gittoes, N.J.L., Sheppard, M.C. & Franklyn, J.A. (1999) Thyroid receptor α1 and α2 mutations in nonfunctioning pituitary tumors. Journal of Clinical Endocrinology and Metabolism, 84, 649-653.
63. McCabe, C.J., Khaira, J.S., Boelaert, K., Heaney, A.P., Tannahill, L.A., Hussain, S., Mitchell, R., Olliff, J., Sheppard, M.C., Franklyn, J.A. & Gittoes, N.J.L. (2002a) Expression of pituitary tumor transforming gene (PTTG) and fibroblast growth factor-2 (FGF-2) in human pituitary adenomas: relationships to clinical tumour behaviour. Clinical Endocrinology, in press.
64. McCabe, C.J., Boelaert, K., Tannahill, L.A., Heaney, A.P., Stratford, A.L., Khaira, J.S., Hussain, S., Sheppard, M.C., Franklyn, J.A. & Gittoes, N.J.L. (2002b) Vascular endothelial growth factor (VEGF), its receptor KDR and pituitary tumor transforming gene in pituitary tumors. Journal of Clinical Endocrinology and Metabolism, 87, 4238-44.
65. Molitch, M.E. & Russel, E.J. (1990) The pituitary incidentaloma. Annals of Internal Medicine, 112, 925-931.
66. Mukai, K., Steljeskog, E.L. & Dehner, L.P. (1986) Pituitary adenomas in patients under 20 years old. A clinicopathological study of 12 cases. Journal of Neurooncology, 4, 79-89.
67. Nakao, H., Koga, M., Arao, N., Kakao, M., Sato, B., Kishimono, S., Saitoh, Y., Arita, N. & Mori, S. (1989) Enzyme immunoassay for oestrogen receptor in human pituitary adenomas. Acta Endocrinologica, 120, 233-238.
68. Namba, H., Matsuo, K. & Fagin, J.A. (1990a) Clonal composition of benign and malignant human thyroid tumors. Journal of Clinical Investigations, 86, 120-125.
69. Namba, H., Rubin, S.A. & Fagin, J.A. (1990b) Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. Molecular Endocrinology, 4, 1474-1479.
70. Nishikawa, R., Cheng, S.Y., Nagashima, R., Huang, H.J., Cavenee, W.K. & Matsutani, M. (1998) Expression of vascular endothelial growth factor in human brain tumours. Acta Neuropathologica (Berlin), 96, 453-462.
71. Ouyang, B., Knauf, J.A., Ain, K., Nacev, B. & Fagin, J.A. (2002) Mechanisms of aneuploidy in thyroid cancer cell lines and tissues: evidence for mitotic checkpoint dysfunction without mutations in BUB1 and BUBR1. Clinical Endocrinology, 56, 341-350.
72. Patel, V.A., Hill, D.J., Eggo, M.C., Sheppard, M.C., Becks, G.P. & Logan, A. (1996) Changes in immunohistochemical localisation of fibroblast growth factor-2, transforming growth factor-beta 1 and thrombospondin-1 are associated with early angiogenic events in the hyperpalstic rat thyroid. Journal of Endocrinology, 148, 485-499.
73. Pei, L. (1999) Pituitary tumor-transforming gene protein associates with ribosomal protein S10 and a novel human homologue of DnaJ in testicular cells. Journal of Biological Chemistry, 274, 3151-3158.
74. Pei, L. (2000) Activation of mitogen-activated protein kinase cascade regulates pituitary tumor-transforming gene transactivation function. Journal of Biological Chemistry, 275, 31191-31198.
75. Pei, L. (2001) Identification of c-myc as a down-stream target for pituitary tumor-transforming gene. Journal of Biological Chemistry, 276, 8484-8491.
76. Pei, L. & Melmed, S. (1997) Isolation and characterization of a pituitary rumor-transforming gene (PTTG). Molecular Endocrinology, 11, 433-441.
77. Pei, L., Melmed, S., Scheithauer, B., Kovacs, K. & Prager, D. (1994) Hras mutations in human pituitary carcinoma metastasis. Journal of Clinical Endocrinology and Metabolism, 78, 842-846.
78. Prezant, T.P., Kadioglu, P. & Melmed, S. (1999) An intronless homolog of human proto-oncogene hPTTG is expressed in pituitary tumours: evidence for hPTTG family. Journal of Clinical Endocrinology and Metabolism, 84, 1149-1152.
79. Ramos-Morales, F., Dominguez, A., Romero, F., Luna, R., Multon, M.C., Pintor-Toro, J.A. & Tortolero, M. (2000) Cell cycle regulated expression and phosphorylation of hpttg proto-oncogene product. Oncogene, 19, 403-409.
80. Roger, P.P., Christophe, D., Dumont, J.E. & Pirson, I. (1997) The dog thyroid primary culture system: a model of the regulation of function, growth and differentiation expression by cAMP and other well-defined signaling cascades. European Journal of Endocrinology, 137, 579-598.
81. Rudner, A.D. & Murray, A.W. (2000) Phosphorylation by Cdc28 activates the Cdc20-dependent activity of the anaphase-promoting complex. Journal of Cell Biology, 149, 1377-1390.
82. Saez, C., Japon, M.A., Ramos-Morales, F., Romero, F., Segura, D.I., Tortolero, M. & Pintor-Toro, J.A. (1999) hpttg is over-expressed in pituitary adenomas and other primary epithelial neoplasias. Oncogene, 18, 5473-5476.
83. Santoro, M., Carlomagno, F. & Hay, I.D. (1992) Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype. Journal of Clinical Investigations, 89, 1517-1522.
84. Schechter, J. & Weiner, R. (1991) Changes in basic fibroblast growth factor coincident with estradiol-induced hyperplasia of the anterior pituitary of Fischer 344 and Sprague-Dawley rats. Endocrinology, 129, 2400-2488.
85. Schlumberger, M.J. (1998) Papillary and follicular thyroid carcinoma. New England Journal of Medicine, 338, 297-306.
86. Schlumberger, M., Challeton, C., De Vathaire, F., Travagli, J.P., Gardet, P., Lumbroso, J.D., Francese, C., Fontaine, F., Ricard, M. & Parmentier, C. (1996) Radioactive iodine treatment and external radiotherapy for lung and bone metasteses from thyroid carcinoma. Journal of Nuclear Medicine, 37, 598-605.
87. Shingu, K., Fujimori, M., Ito, K., Hama, Y., Kasuga, Y., Kobayashi, S., Itoh, N. & Amano, J. (1998) Expression of fibroblast growth factor-2 and fibroblast growth factor receptor-1 in thyroid diseases: difference between neoplasms and hyperplastic lesions. Endocrine Journal, 45, 35-43.
88. Shteinberg, M., Protopopov, Y., Listovsky, T., Brandeis, M. & Hershko, A. (1999) Phosphorylation of the cyclosome is required for its stimulation by Fizzy/cdc20. Biochemistry and Biophysics Research Communications, 260, 193-198.
89. Spada, A., Arosio, M., Bochicchio, D., Bazzorini, N., Vallar, L., Bassetti, M. & Faglia, G. (1990) Clinical, biochemical and morphological correlates in patients bearing growth hormone-secreting pituitary tumours with or without constitutively active adenyl cyclase. Journal of Clinical Endocrinology and Metabolism, 71, 1421-1426.
90. Stefeananu, L., Kovacs, K., Horvath, E., Lloyd, R.V., Buchfelder, M., Fahlbusch, R. & Smyth, H. (1994) In situ hybridisation study of oestrogen receptor messenger ribonucleic acid in human adenohypophyseal cells and pituitary adenomas. Journal of Clinical Endocrinology and Metabolism, 78, 83-88.
91. Sturgis, C.D., Caraway, N.P., Johnston, D.A., Sherman, S.I., Kidd, L. & Katz, R.L. (1999) Image analysis of papillary thyroid carcinoma fine-needle aspirates: significant association between aneuploidy and death from disease. Cancer, 87, 155-160.
92. Surez, H.G., du Villard, J.A., Caillou, B., Schlumberger, M., Parmentier, C. & Monie, R. (1991) gsp mutations in human thyroid tumors. Oncogene, 6, 677-679.
93. Terada, T., Kovacs, K., Stefaneanu, L. & Horvath, E. (1995) Incidence, pathology and recurrence of pituitary adenomas: study of 647 unselected surgical cases. Endocrine Pathology, 6, 301-310.
94. Thapar, K., Kovacs, K., Scheithauer, B.W., Stefaneanu, L., Horvath, E., Pernicone, P.J., Murray, D. & Laws, E. Jr (1996a) Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery, 38, 99-106.
95. Thapar, K., Scheithauer, B.W., Kovacs, K., Pernicone, P.J. & Laws, E. Jr (1996b) p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions. Neurosurgery, 38, 763-770.
96. Thompson, S.D., Franklyn, J.A., Watkinson, J.C., Verhaeg, J.M., Sheppard, M.C. & Eggo, M.C. (1998) Fibroblast growth factors 1 and 2 and fibroblast growth factor receptor 1 are elevated in thyroid hyperplasia. Journal of Clinical Endocrinology and Metabolism, 83, 1336-1341.
97. Trapasso, F., Martelli, M.L., Battaglia, C., Angotti, E., Mele, E., Stella, A., Samarut, J., Avvedimento, V.E. & Fusco, A. (1996) The v-erbA oncogene selectively inhibits iodide uptake in rat thyroid cells. Oncogene, 2, 1879-1888.
98. Trovato, M., Villari, D., Ruggieri, R.M., Quattrocchi, E., Fragetta, F., Simone, A., Scarfi, R., Magro, G., Batolo, D., Trimarchi, F. & Benvenga, S. (2001) Expression of CD30 ligand and CD30 receptor in normal thyroid and benign and malignant thyroid nodules. Thyroid, 11, 621-628.
99. Tung, W.S., Shevlin, D.W., Kaleem, Z., Tribune, D.J., Wells, S.A. & Goodfellow, P.J. (1997) Allelotype of follicular thyroid carcinoma reveals genetic instability consistent with frequent nondisjunctional chromosomal loss. Genes Chromosomes Cancer, 19, 43-51.
100. Utiger, R.D. (1997) Follow-up of patients with thyroid carcinoma. New England Journal of Medicine, 337, 928-930.
101. Wang, Z. & Melmed, S. (2000) Pituitary tumor transforming gene (PTTG) transforming and transactivation activity. Journal of Biological Chemistry, 275, 7459-7461.
102. Wang, Z., Yu, R. & Melmed, S. (2001) Mice lacking pituitary tumor transforming gene show testicular and splenic hypoplasia, thymic hyperplasia, thrombocytopenia, aberrant cell cycle progression, and premature centromere division. Molecular Endocrinology, 11, 1870-1879.
103. Ward, L.S., Brenta, G., Medvedovic, M. & Fagin, J.A. (1998) Studies of allelic loss in thyroid tumors reveal major differences in chromosomal instability between papillary and follicular lesions. Journal of Clinical Endocrinology and Metabolism, 83, 525-530.
104. Wilson, C.B. (1997) Extensive personal experience: surgical management of pituitary tumors. Journal of Clinical Endocrinology and Metabolism, 82, 2381-2385.
105. Wlodarska, I., Mecucci, C., Baens, M., Marynen, P. & van den Berghe, H. (1996) ETV6 gene rearrangements in hematopoietic malignant disorders. Leukocyte Lymphoma, 23, 287-295.
106. Yu, R., Ren, S.-G., Horwitz, G.A., Wang, Z. & Melmed, S. (2000a) Pituitary tumor transforming gene (PTTG) regulates placental JEG-3 cell division and survival: evidence from live cell imaging. Molecular Endocrinology, 14, 1137-1146.
107. Yu, R., Heaney, A., Lu, W., Chen, J. & Melmed, S. (2000b) Pituitary tumor transforming gene (PTTG) causes aneuploidy and p53-dependent and p53-independent apoptosis. Journal of Biological Chemistry, 275, 36502-36505.
108. Zafar, M., Ezzat, S., Ramayar, L., Pan, N., Smyth, H.S. & Asa, S.L. (1995) Cell-specific expression of oestrogen receptor in the human pituitary and its adenomas. Journal of Clinical Endocrinology and Metabolism, 80, 3621-3627.
109. Zakarija, M. & McKenzie, J.M. (1989) Variations in the culture medium for FRTL5 cells: effects on growth and iodide uptake. Endocrinology, 125, 1253-1259.
110. Zedenius, J., Wallin, G., Svensson, A., Grimelius, L., Hoog, A., Lundell, G., Backdahl, M. & Larsson, C. (1995) Allelotyping of follicular thyroid tumors. Human Genetics, 96, 27-32.
111. Zhang, X., Horwitz, G.A., Prezant, T.P., Valentini, A., Nakashima, M., Bronstein, M.D. & Melmed, S. (1999a) Structure, expression and function of human pituitary tumor transforming gene (PTTG). Molecular Endocrinology, 13, 156-166.
112. Zhang, X., Horwitz, G.A., Heaney, A.P., Nakashima, M., Prezant, T.P., Bronstein, M.D. & Melmed, S. (1999b) Pituitary tumor transforming gene expression in human pituitary adenomas. Journal of Clinical Endocrinology and Metabolism, 84, 761-767.
113. Zimmering, M.B., Katsumato, N., Sato, Y., Brandi, M.L., Aurbach, G.D. & Marx, S.J. (1993) Increased basic fibroblast growth factor in plasma from multiple endocrine neoplasia type-1: relation to pituitary tumour. Journal of Clinical Endocrinology and Metabolism, 76, 1182-1187.
114. Zou, H., McGarry, T.J., Bernal, T. & Kirschner, M.W. (1999) Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. Science, 285, 418-422.
115. Zur, A. & Brandeis, M. (2001) Securin degradation is mediated by fzy and fzr, and is required for complete chromatid separation but not for cytokinesis. EMBO Journal, 20, 792-801.